Last $14.40 USD
Change Today +0.20 / 1.41%
Volume 27.8K
VCYT On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 4:30 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$14.29
Previous Close
$14.20
Day High
$14.63
Day Low
$14.29
52 Week High
03/19/14 - $19.00
52 Week Low
11/7/13 - $10.88
Market Cap
304.9M
Average Volume 10 Days
46.5K
EPS TTM
--
Shares Outstanding
21.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

115 Employees
Last Reported Date: 03/20/14
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $380.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $201.0K
Chief Commercial Officer
Total Annual Compensation: $316.3K
Compensation as of Fiscal Year 2013.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Appoints Duncan T. Powell as Principal Accounting Officer

Effective July 10, 2014, the Board of Directors of Veracyte, Inc. appointed Duncan T. Powell as the company's Principal Accounting Officer. Mr. Powell became the company's Senior Vice President, Finance on July 10, 2014. Prior to joining the company, Mr. Powell served as Senior Vice President, Finance of Risk Management Solutions, Inc.

Veracyte, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 11:30 AM

Veracyte, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 11:30 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.

Veracyte, Inc. Appoints Ernst & Young LLP and Replaces PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm

On June 4, 2014, the audit committee of the Board of Directors of Veracyte, Inc. approved the dismissal of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm. On June 4, 2014, the audit committee approved the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $14.40 USD +0.20

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $27.49 USD -0.11
Laboratory Corp of America Holdings $105.63 USD +0.03
Response Genetics Inc $0.80 USD +0.0099
Rosetta Genomics Ltd $4.00 USD +0.04
TrovaGene Inc $3.26 USD +0.07
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.